Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis

Mary Kate Lockhart; Elaine C Siegfried

doi:10.1016/j.det.2021.12.002

Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis

Dermatol Clin. 2022 Apr;40(2):137-143. doi: 10.1016/j.det.2021.12.002.

Authors

Mary Kate Lockhart¹, Elaine C Siegfried²

Affiliations

¹ Division of Dermatology, Department of Pediatrics, Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 1465 South Grand Boulevard, St. Louis, MO 63104, USA. Electronic address: Marykate.k.lockhart@health.slu.edu.
² Division of Dermatology, Department of Pediatrics, Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 1465 South Grand Boulevard, St. Louis, MO 63104, USA.

PMID: 35366968
DOI: 10.1016/j.det.2021.12.002

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in children. Standard-of-care treatment has been topical therapy. Oral corticosteroids are also commonly used to treat intermittent flares, despite guidelines that recommend against this practice. In 2017, the first targeted biologic agent indicated for moderate-severe AD in adults received US Food and Drug Administration approval. The success of this drug, dupilumab, filled a significant unmet medical need and inspired additional interest in new drug development. This article summarizes safe and effective use of systemic therapy for moderate-severe AD in pediatric patients, highlighting dupilumab and the most promising emerging treatments.

Keywords: Atopic dermatitis; Biologic; Comorbidities; Dupilumab; Quality of life; Safety.

Publication types

Review

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Adult
Child
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Skin

Substances

Adrenal Cortex Hormones